FIGHTINGDRUGFAILURE

Priorities and Standards in Pharmacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy

 Coordinatore ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH 

 Organization address address: AUERBACHSTRASSE 112
city: STUTTGART
postcode: 70376

contact info
Titolo: Prof.
Nome: Hiltrud
Cognome: Brauch
Email: send email
Telefono: +49 711 81 01 3705
Fax: +49 711 85 92 95

 Nazionalità Coordinatore Germany [DE]
 Totale costo 3˙187˙750 €
 EC contributo 3˙187˙750 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-ITN-2008
 Funding Scheme MC-ITN
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-10-01   -   2013-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH

 Organization address address: AUERBACHSTRASSE 112
city: STUTTGART
postcode: 70376

contact info
Titolo: Prof.
Nome: Hiltrud
Cognome: Brauch
Email: send email
Telefono: +49 711 81 01 3705
Fax: +49 711 85 92 95

DE (STUTTGART) coordinator 1˙270˙261.00
2    THE UNIVERSITY OF LIVERPOOL

 Organization address address: Brownlow Hill, Foundation Building 765
city: LIVERPOOL
postcode: L69 7ZX

contact info
Titolo: Ms.
Nome: Karin
Cognome: Alecock
Email: send email
Telefono: +44 151 794 8208
Fax: +44 151 794 8728

UK (LIVERPOOL) participant 1˙051˙440.00
3    UNIVERZA V LJUBLJANI

 Organization address address: KONGRESNI TRG 12
city: LJUBLJANA
postcode: 1000

contact info
Titolo: Prof.
Nome: Damjana
Cognome: Rozman
Email: send email
Telefono: +386 1 5437591
Fax: +386 1 5437588

SI (LJUBLJANA) participant 401˙335.00
4    N.N. Petrov Institute of Oncology

 Organization address address: "Pesochny-2, Leningradskaya str. 68"
city: St.-Petersburg
postcode: 197758

contact info
Titolo: Prof.
Nome: Evgeny
Cognome: Imyanitov
Email: send email
Telefono: +7 812 5968951
Fax: +7 812 5968947

RU (St.-Petersburg) participant 241˙054.00
5    LAB 21 LIMITED

 Organization address address: Cambridge Science Park 184
city: Cambridge
postcode: CB4 0GA

contact info
Titolo: Dr.
Nome: Berwyn
Cognome: Clarke
Email: send email
Telefono: +44 1223 395461
Fax: +44 7769 698686

UK (Cambridge) participant 223˙660.00
6    Delphic Diagnostics Ltd

 Organization address address: ALBEMARLE STREET 26A
city: LONDON
postcode: W1S 4HY

contact info
Titolo: Prof.
Nome: David John
Cognome: Back
Email: send email
Telefono: +44 151 794 5547
Fax: +44 151 794 5656

UK (LONDON) participant 0.00
7    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Hiltrud
Cognome: Brauch
Email: send email
Telefono: +49 711 81013705
Fax: +49 711 859295

DE (TUEBINGEN) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

agents    genetic    clinicians    received    itn    therapy    relate    pharmacogenomics    pooled    differences    training    clinical    women    independent    sharing    young    brca    train    cancer    neoadjuvant    recurrence    breast    tamoxifen    outcomes    going    tumour    risk    fightingdrugfailure    laboratories    patients    materials    responsible    retrieve    basic    variations    translational    mutation    patient    drug    variation    treatment    polymorphisms    cytotoxic    drugs    skills    mir    investigators    performing   

 Obiettivo del progetto (Objective)

'Pharmacogenomics is the scientific discipline that relates inter-individual variation in drug response to genetic variation. While there have been major advances in basic genomic knowledge and genotyping technologies, translation into clinical practice has been slow. It is essential we quicken the pace of translational research in pharmacogenomics - at present, we cannot define which patients are going to respond to drugs, and which patients are going to develop adverse drug reactions. In this ITN, our concerted action across the EU, in cooperation with US researchers will train young investigators and clinicians (14 ESR and 2 ER) to establish, evaluate and retrieve relevant genetic information from patients, and relate it to clinical outcomes of drug therapy. This will be achieved through sharing patient materials, performing pooled analyses, transfer of knowledge and skills across laboratories and provide access to high-throughput technology platforms between 5 academic (3 EU, 1 ICPC, 1 OTC partners) and 4 industry partners (3 EU, 1AC partner). This will enhance translational research, promote uniform drug treatment standards throughout Europe and worldwide, and improve the competitiveness of the EU in this emerging and exciting field.'

Introduzione (Teaser)

Patient response to drug treatment shows a broad range of variations. Pharmacogenomics research is addressing genetic and epigenetic differences responsible for the variations in therapeutic response.

Descrizione progetto (Article)

Despite major advances in drug treatment and therapy, it is still difficult for doctors to determine the right medication and dose for every patient. The chosen drug should be the most effective for a specific person and condition with the fewest possible side-effects. Genome variability has been recognised as a reason for the differences in drug response (pharmacogenomics).

The Marie Curie Initial Training Network (ITN) funded the http://www.fightingdrugfailure.net (FIGHTINGDRUGFAILURE) initiative to train young investigators and clinicians in pharmacogenomics. The training involved international collaborations in order to establish, evaluate and retrieve relevant genetic information from patients and relate it to clinical outcomes of drug therapy. This was achieved through sharing patient materials, performing pooled analyses, and transferring knowledge and skills across laboratories.

The project studied healthy women and the prediction of their risk to develop breast cancer as a consequence of using long-term hormonal treatment for the relief of menopausal symptoms. It involved personalised assessment for the risk of recurrence in patients who received the selective estrogen receptor modulator tamoxifen for the control of their disease. It also focusedon patients who received cytotoxic agents for the neoadjuvant treatment of breast cancer caused by BRCA1 mutation.

Rresearchers found that the HSD17B1_G gene allele protected women from developing breast cancer when they had used hormone replacement therapy for more than 10 years. In the case of tamoxifen treatment, they identified polymorphisms of the CYP2D6 enzyme (responsible for the formation of the active metabolite) as a clinical outcome predictor. Moreover, tumour-associated microRNAs miR-126 and miR-10a were identified as independent predictors for tumour recurrence. In the case of neoadjuvant treatment with cytotoxic agents, the underlying BRCA1 mutation was predictive of a favourable response.

The researcher also addressed aspects of safer pharmacotherapy for frequently used drugs. They included anticonvulsants, antiretroviral and chemotherapeutic compounds as well as glucocorticoids, all of which are known to cause severe side-effects. In addition, specific hepatic factors and cholesterol-associated pathologies were analysed to identify more potential drug targets. Systems biology techniquess revealed entire pathways for potential improvements to drug treatment.

Overall, FIGHTINGDRUGFAILURE proved that genetic polymorphisms have great potential as biomarkers to improve individualised treatment strategies. The newly acquired basic and specialised knowledge equipped 17 young investigators and clinicians for their future independent research.

Altri progetti dello stesso programma (FP7-PEOPLE)

ENDOCYTIC REGULATORS (2010)

A comprehensive analysis of essential protein regulators of clathrin-mediated endocytic pathway

Read More  

NLAMATHMODELS (2009)

"Nonlinear Analysis in Mathematical Models: Heat Damage, Stability of Nonlinear Waves and Spectral-Scattering Problems"

Read More  

NEWCOMPACTISM (2012)

New Urbanism vs Compact City: Investigation of the relationships between urban micro- and macro- scale effects on travel behaviour

Read More